The market is expected to grow at a steady CAGR forecast till 2030 owing to the increase in incidence of cardiovascular diseases, growing awareness regarding health, and increase in product development activities by key market players across the globe.
The global hemodynamic monitoring systems market was valued at USD 924 million in 2023, growing at a CAGR of 6.29% during the forecast period from 2024 to 2030, in order to reach USD 1.33 billion by 2030. The growing prevalence of cardiovascular conditions, such as heart failure and hypertension, underscores the need for continuous and accurate monitoring to manage these diseases effectively and improve patient outcomes. Concurrently, heightened health awareness among both patients and healthcare providers drives demand for advanced monitoring solutions that enable early detection and intervention. Furthermore, increased product development by key market players characterized by technological innovations, such as enhanced sensors and integration with electronic health records, further propels market growth by offering more precise, user-friendly, and integrated monitoring solutions. Together, these factors contribute to the expanding adoption and advancement of hemodynamic monitoring systems and propels market growth during forecast period from 2024 to 2030.
Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, was the most commonly diagnosed worldwide, affected an estimated 200 million people globally. Approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.
As per the latest data provided by World Health Organization (2023), an estimated 1.28 billion adults aged 30-79 years worldwide had hypertension, with most (two-thirds) residing in low- and middle-income countries. An estimated 46% of adults with hypertension were unaware of their condition, and less than half (42%) had been diagnosed and treated. As cardiovascular conditions, such as heart disease, heart failure, and hypertension, become more prevalent globally, there is an increased demand for sophisticated monitoring solutions that can provide real-time insights into patients' cardiovascular health. Hemodynamic monitoring systems offer vital capabilities to track key physiological parameters, such as blood pressure, cardiac output, and fluid status, which are crucial for diagnosing, treating, and managing these conditions. By enabling clinicians to monitor changes in hemodynamic status promptly and accurately, these systems help in optimizing treatment plans, preventing complications, and improving overall patient outcomes thereby escalating the overall market of hemodynamic monitoring systems across the globe.
Along with the factors mentioned above, technological advancements in the field of hemodynamic monitoring systems such as the development of new techniques to enhance the yield and diagnostic accuracy are also expected to aid in the growth of the hemodynamic monitoring systems market. For instance, in September 2021, FDA cleared Caretaker Medical’s VitalStream™ wireless platform for continuous noninvasive blood pressure and hemodynamic monitoring.
However, the risk associated with invasive hemodynamic monitoring, such as sepsis, bleeding, hemorrhage, thrombosis, and accuracy concerns is expected to restrain the growth of hemodynamic monitoring systems.
In the product segment of the overall hemodynamic monitoring systems market, the non-invasive hemodynamic monitoring systems are expected to hold the largest share in the year 2023. Non-invasive hemodynamic monitors are significantly boosting the overall market for hemodynamic monitoring systems by offering advanced solutions that enhance patient comfort, improve clinical outcomes, and streamline healthcare workflows. These monitors provide accurate and continuous hemodynamic data without the need for invasive procedures, which reduces patient risk, minimizes discomfort, and lowers the potential for complications. As a result, they are becoming increasingly preferred in various clinical settings, including critical care, emergency medicine, and routine patient monitoring. The ability of non-invasive monitors to deliver real-time data on critical parameters such as blood pressure, cardiac output, and fluid status enables healthcare providers to make timely and informed decisions, optimizing treatment strategies and improving patient management.
Consequently, the advancement and integration of these monitors into clinical practice are propelling the market growth by enhancing the overall effectiveness and efficiency of hemodynamic monitoring systems. For instance, in January 2024, Nanowear, a leader in healthcare-at-home remote diagnostics, announced that its nanotechnology-enabled wearable and software platform, SimpleSense™, received FDA 510(k) clearance for its novel AI-enabled Software-as-a-Medical Device (SaMD). As the first non-invasive, cuffless, continuous blood pressure monitor and diagnostic, SimpleSense-BP represented a significant advancement in clinical diagnostic management of hypertension, adding to the wearable platform’s previously cleared cardiopulmonary diagnostics.
Hence, all the above-mentioned factors are expected to generate considerable revenue of the segment pushing the overall growth of the global hemodynamic monitoring systems market during the forecast period.
According to the latest data provided by the Centre for Disease Control and Prevention (2023), approximately, 48.1% population of adults age 18 and older in the United States are living with hypertension.
According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.
These conditions necessitate precise and continuous monitoring to manage and mitigate the risks associated with cardiovascular events. As healthcare providers and patients seek effective tools to monitor heart function, blood pressure, and overall cardiovascular health, hemodynamic monitoring systems become essential. These systems provide critical insights into cardiovascular performance, enabling timely interventions and personalized treatment plans. Thus, the increasing burden of these diseases fuels the market of hemodynamic monitoring system as healthcare systems invest in advanced monitoring technologies to improve patient outcomes and manage chronic conditions effectively thereby escalating the market across the region.
Furthermore, the increased emphasis on product development activities and high interest of device manufacturers in accessing local markets further aid in the growth of the regional markets for hemodynamic monitoring systems. For instance, in March 2021, FDA granted De Novo classification to Fifth Eye's continuous hemodynamic status monitoring tool. The analytic for hemodynamic instability tool can identify hemodynamic instability with 96% sensitivity and detect stable patients with 85% specificity. The product launches in the local markets correlate to a significant reduction in costs thereby making them affordable for end-users which in turn drives the product demand in the market.
Therefore, the interplay of above mentioned various factors in the region are expected to boost the North America hemodynamic monitoring systems market during the forecast period.
This product will be delivered within 2 business days.
The global hemodynamic monitoring systems market was valued at USD 924 million in 2023, growing at a CAGR of 6.29% during the forecast period from 2024 to 2030, in order to reach USD 1.33 billion by 2030. The growing prevalence of cardiovascular conditions, such as heart failure and hypertension, underscores the need for continuous and accurate monitoring to manage these diseases effectively and improve patient outcomes. Concurrently, heightened health awareness among both patients and healthcare providers drives demand for advanced monitoring solutions that enable early detection and intervention. Furthermore, increased product development by key market players characterized by technological innovations, such as enhanced sensors and integration with electronic health records, further propels market growth by offering more precise, user-friendly, and integrated monitoring solutions. Together, these factors contribute to the expanding adoption and advancement of hemodynamic monitoring systems and propels market growth during forecast period from 2024 to 2030.
Hemodynamic Monitoring Systems Market Dynamics:
According to a recent data provided by British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, lived with heart and circulatory diseases. Additionally, as per the same source, the prevalence of heart and circulatory diseases was 100 million in Europe and 340 million in Asia and Australia in 2021.Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, was the most commonly diagnosed worldwide, affected an estimated 200 million people globally. Approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.
As per the latest data provided by World Health Organization (2023), an estimated 1.28 billion adults aged 30-79 years worldwide had hypertension, with most (two-thirds) residing in low- and middle-income countries. An estimated 46% of adults with hypertension were unaware of their condition, and less than half (42%) had been diagnosed and treated. As cardiovascular conditions, such as heart disease, heart failure, and hypertension, become more prevalent globally, there is an increased demand for sophisticated monitoring solutions that can provide real-time insights into patients' cardiovascular health. Hemodynamic monitoring systems offer vital capabilities to track key physiological parameters, such as blood pressure, cardiac output, and fluid status, which are crucial for diagnosing, treating, and managing these conditions. By enabling clinicians to monitor changes in hemodynamic status promptly and accurately, these systems help in optimizing treatment plans, preventing complications, and improving overall patient outcomes thereby escalating the overall market of hemodynamic monitoring systems across the globe.
Along with the factors mentioned above, technological advancements in the field of hemodynamic monitoring systems such as the development of new techniques to enhance the yield and diagnostic accuracy are also expected to aid in the growth of the hemodynamic monitoring systems market. For instance, in September 2021, FDA cleared Caretaker Medical’s VitalStream™ wireless platform for continuous noninvasive blood pressure and hemodynamic monitoring.
However, the risk associated with invasive hemodynamic monitoring, such as sepsis, bleeding, hemorrhage, thrombosis, and accuracy concerns is expected to restrain the growth of hemodynamic monitoring systems.
Hemodynamic Monitoring Systems Market Segment Analysis:
Hemodynamic Monitoring Systems Market by Product (Systems and Disposables), Type (Invasive Hemodynamic Monitoring, Minimally Invasive Hemodynamic Monitoring, and Non-Invasive Hemodynamic Monitoring), End-User (Hospitals, Ambulatory Care Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)In the product segment of the overall hemodynamic monitoring systems market, the non-invasive hemodynamic monitoring systems are expected to hold the largest share in the year 2023. Non-invasive hemodynamic monitors are significantly boosting the overall market for hemodynamic monitoring systems by offering advanced solutions that enhance patient comfort, improve clinical outcomes, and streamline healthcare workflows. These monitors provide accurate and continuous hemodynamic data without the need for invasive procedures, which reduces patient risk, minimizes discomfort, and lowers the potential for complications. As a result, they are becoming increasingly preferred in various clinical settings, including critical care, emergency medicine, and routine patient monitoring. The ability of non-invasive monitors to deliver real-time data on critical parameters such as blood pressure, cardiac output, and fluid status enables healthcare providers to make timely and informed decisions, optimizing treatment strategies and improving patient management.
Consequently, the advancement and integration of these monitors into clinical practice are propelling the market growth by enhancing the overall effectiveness and efficiency of hemodynamic monitoring systems. For instance, in January 2024, Nanowear, a leader in healthcare-at-home remote diagnostics, announced that its nanotechnology-enabled wearable and software platform, SimpleSense™, received FDA 510(k) clearance for its novel AI-enabled Software-as-a-Medical Device (SaMD). As the first non-invasive, cuffless, continuous blood pressure monitor and diagnostic, SimpleSense-BP represented a significant advancement in clinical diagnostic management of hypertension, adding to the wearable platform’s previously cleared cardiopulmonary diagnostics.
Hence, all the above-mentioned factors are expected to generate considerable revenue of the segment pushing the overall growth of the global hemodynamic monitoring systems market during the forecast period.
North America is expected to dominate the overall hemodynamic monitoring systems market:
Among all the regions, North America is expected to hold the largest share in the global hemodynamic monitoring systems market in 2023. Owing to significant growth factors such as growing prevalence of hypertension and cardiovascular diseases. Additionally, increasing health awareness, technological advancement in hemodynamic monitoring system, and rising government initiatives are expected to aid in the growth of the North American hemodynamic monitoring systems market during the forecast period from 2024 to 2030.According to the latest data provided by the Centre for Disease Control and Prevention (2023), approximately, 48.1% population of adults age 18 and older in the United States are living with hypertension.
According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.
These conditions necessitate precise and continuous monitoring to manage and mitigate the risks associated with cardiovascular events. As healthcare providers and patients seek effective tools to monitor heart function, blood pressure, and overall cardiovascular health, hemodynamic monitoring systems become essential. These systems provide critical insights into cardiovascular performance, enabling timely interventions and personalized treatment plans. Thus, the increasing burden of these diseases fuels the market of hemodynamic monitoring system as healthcare systems invest in advanced monitoring technologies to improve patient outcomes and manage chronic conditions effectively thereby escalating the market across the region.
Furthermore, the increased emphasis on product development activities and high interest of device manufacturers in accessing local markets further aid in the growth of the regional markets for hemodynamic monitoring systems. For instance, in March 2021, FDA granted De Novo classification to Fifth Eye's continuous hemodynamic status monitoring tool. The analytic for hemodynamic instability tool can identify hemodynamic instability with 96% sensitivity and detect stable patients with 85% specificity. The product launches in the local markets correlate to a significant reduction in costs thereby making them affordable for end-users which in turn drives the product demand in the market.
Therefore, the interplay of above mentioned various factors in the region are expected to boost the North America hemodynamic monitoring systems market during the forecast period.
Hemodynamic Monitoring Systems Market Key Players:
Some of the key market players operating in the hemodynamic monitoring systems market include Edwards Lifesciences Corporation, Getinge AB, Deltex Medical Limited, ICU Medical, Inc., CNSystems Medizintechnik GmbH, Caretaker, LLC, Osypka Medical GmbH, Baxter International Inc. (Cheetah Medical, Inc.), Shenzhen Comen Medical Instruments Co., Ltd., General Meditech Inc., Drägerwerk AG & Co. KGaA, General Electric Company, Smiths Group, Transonic Systems Inc., EMTEL Śliwa sp. K, NIMedical, Masimo (LiDCO Group Plc), Nihon Kohden Corporation, Hemo Sapiens Inc., Koninklijke Philips N.V., and others.Recent Developmental Activities in the Hemodynamic Monitoring Systems Market:
- In July 2024, Getinge launched Pulsiocare - the next generation in hemodynamic monitor.
- In June 2022, Clarius partnered with ImaCor to make available handheld hemodynamic ultrasound tech. The ZuraTM Handheld Hemodynamic UltrasoundTM system powered by Clarius provides an instant, clear window to directly visualize preload and contractility over time, having received clearance by the U.S. Food and Drug Administration to help clinicians make the right decisions, at the right time.
Key Takeaways From the Hemodynamic Monitoring Systems Market Report Study:
- Market size analysis for current hemodynamic monitoring systems size (2023), and market forecast for 6 years (2024 to 2030)
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
- Key companies dominating the hemodynamic monitoring systems market
- Various opportunities available for the other competitors in the hemodynamic monitoring systems market space.
- What are the top-performing segments in 2023? How these segments will perform in 2030?
- Which are the top-performing regions and countries in the current hemodynamic monitoring systems market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for hemodynamic monitoring systems market growth in the coming future?
Target Audience who can be Benefited From This Hemodynamic Monitoring Systems Market Report Study:
- Hemodynamic monitoring systems product providers
- Research organizations and consulting companies
- Hemodynamic monitoring systems -related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in hemodynamic monitoring systems
- Various end-users who want to know more about the hemodynamic monitoring systems market and the latest technological developments in the hemodynamic monitoring systems market.
Frequently Asked Questions for the Hemodynamic Monitoring Systems Market:
1. What are hemodynamic monitoring systems?
- Hemodynamic monitoring systems are medical instrument used to accurately monitor the blood flow through the cardiovascular system as well as monitor the responses of patients. These devices can also help in recognizing the dysfunctioning of other vital organs hence, improving patient safety.
2. What is the market for hemodynamic monitoring systems?
- The global hemodynamic monitoring systems market was valued at USD 924 million in 2023, growing at a CAGR of 6.29% during the forecast period from 2024 to 2030, in order to reach USD 1.33 billion by 2030.
3. What are the drivers for the hemodynamic monitoring systems market?
- The growing prevalence of cardiovascular conditions, such as heart failure and hypertension, underscores the need for continuous and accurate monitoring to manage these diseases effectively and improve patient outcomes. Concurrently, heightened health awareness among both patients and healthcare providers drives demand for advanced monitoring solutions that enable early detection and intervention. Furthermore, increased product development by key market players characterized by technological innovations, such as enhanced sensors and integration with electronic health records, further propels market growth by offering more precise, user-friendly, and integrated monitoring solutions. Together, these factors contribute to the expanding adoption and advancement of hemodynamic monitoring systems and propels market growth during forecast period from 2024 to 2030.
4. Who are the key players operating in the hemodynamic monitoring systems market?
- Some of the key market players operating in the hemodynamic monitoring systems market include Edwards Lifesciences Corporation, Getinge AB, Deltex Medical Limited, ICU Medical, Inc., CNSystems Medizintechnik GmbH, Caretaker, LLC, Osypka Medical GmbH, Baxter International Inc. (Cheetah Medical, Inc.), Shenzhen Comen Medical Instruments Co., Ltd., General Meditech Inc., Drägerwerk AG & Co. KGaA, General Electric Company, Smiths Group, Transonic Systems Inc., EMTEL Śliwa sp. K, NIMedical, Masimo (LiDCO Group Plc), Nihon Kohden Corporation, Hemo Sapiens Inc., Koninklijke Philips N.V., and others.
5. Which region has the highest share in the hemodynamic monitoring systems market?
- Among all the regions, North America is expected to hold the largest share in the global hemodynamic monitoring systems market in 2023. Owing to significant growth factors such as growing prevalence of hypertension and cardiovascular diseases. Additionally, increasing health awareness, technological advancement in hemodynamic monitoring system, and rising government initiatives are expected to aid in the growth of the North American hemodynamic monitoring systems market during the forecast period from 2024 to 2030.
This product will be delivered within 2 business days.
Table of Contents
1. Hemodynamic Monitoring Systems Market Report Introduction
2. Hemodynamic Monitoring Systems Market Executive Summary
4. Regulatory Analysis
5. Hemodynamic Monitoring Systems Market Key Factors Analysis
6. Hemodynamic Monitoring Systems Market Porter’s Five Forces Analysis
7. Hemodynamic Monitoring Systems Market Assessment
8. Hemodynamic Monitoring Systems Market Company and Product Profiles
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Edwards Lifesciences Corporation
- Getinge AB
- Deltex Medical Limited
- ICU Medical, Inc.
- CNSystems Medizintechnik GmbH
- Caretaker, LLC
- Osypka Medical GmbH
- Baxter International Inc. (Cheetah Medical, Inc.)
- Shenzhen Comen Medical Instruments Co., Ltd.
- General Meditech Inc.
- Drägerwerk AG & Co. KGaA
- General Electric Company
- Smiths Group
- Transonic Systems Inc.
- EMTEL Śliwa sp. K
- NIMedical
- Masimo (LiDCO Group Plc)
- Nihon Kohden Corporation
- Hemo Sapiens Inc.
- Koninklijke Philips N.V.